Interleukin-34 Sustains Pro-tumorigenic Signals in Colon Cancer Tissue
Overview
Authors
Affiliations
Interleukin-34 (IL-34), a cytokine produced by a wide range of cells, binds to the macrophage colony-stimulating factor receptor (M-CSFR-1) and receptor-type protein-tyrosine phosphatase zeta (PTP-z) and controls myeloid cell differentiation, proliferation and survival. various types of cancers over-express IL-34 but the role of the cytokine in colorectal cancer (CRC) remains unknown. We here investigated the expression and functional role of IL-34 in CRC. A more pronounced expression of IL-34 was seen in CRC samples as compared to matched normal/benign colonic samples and this occurred at both RNA and protein level. Immunohistochemical analysis of CRC tissue samples showed that both cancer cells and lamina propria mononuclear cells over-expressed IL-34. Additionally, CRC cells expressed both M-CSFR-1 and PTP-z, thus suggesting that CRC cells can be responsive to IL-34. Indeed, stimulation of DLD-1 cancer cells with IL-34, but not with MSCF1, enhanced the cell proliferation and cell invasion without affecting cell survival. Analysis of intracellular signals underlying the mitogenic effect of IL-34 revealed that the cytokine enhanced activation of ERK1/2 and pharmacologic inhibition of ERK1/2 abrogated IL-34-driven cell proliferation. Consistently, IL-34 knockdown in HT-29 cells with a specific IL-34 antisense oligonucleotide reduced ERK1/2 activation, cell proliferation and enhanced the susceptibility of cells to Oxaliplatin-induced death. This is the first study showing up-regulation of IL-34 in CRC and suggesting a role for this cytokine in colon tumorigenesis.
CSF-1R in Cancer: More than a Myeloid Cell Receptor.
Cersosimo F, Lonardi S, Ulivieri C, Martini P, Morrione A, Vermi W Cancers (Basel). 2024; 16(2).
PMID: 38254773 PMC: 10814415. DOI: 10.3390/cancers16020282.
Han N, Wada H, Kobayashi T, Otsuka R, Seino K Oncoimmunology. 2023; 12(1):2238499.
PMID: 37533702 PMC: 10392724. DOI: 10.1080/2162402X.2023.2238499.
Interleukin-34 and immune checkpoint inhibitors: Unified weapons against cancer.
Alshaebi F, Safi M, Algabri Y, Al-Azab M, Aldanakh A, Alradhi M Front Oncol. 2023; 13:1099696.
PMID: 36798830 PMC: 9927403. DOI: 10.3389/fonc.2023.1099696.
Targeted Therapy of Interleukin-34 as a Promising Approach to Overcome Cancer Therapy Resistance.
Monteleone G, Franze E, Maresca C, Colella M, Pacifico T, Stolfi C Cancers (Basel). 2023; 15(3).
PMID: 36765929 PMC: 9913481. DOI: 10.3390/cancers15030971.
Interleukin-34 deficiency aggravates development of colitis and colitis-associated cancer in mice.
Liu Z, Chen W, Wang Y, Chen B, Liu Y, Cheng T World J Gastroenterol. 2023; 28(47):6752-6768.
PMID: 36620338 PMC: 9813936. DOI: 10.3748/wjg.v28.i47.6752.